Perbedaan Brigit Biofarmaka Teknologi Tbk. dan Super Bank Indonesia Tbk.: Brigit Biofarmaka Teknologi Tbk. diperdagangkan di Rp240 (kapitalisasi pasar 166,01 M, volume 24 jam 324 rb), sedangkan Super Bank Indonesia Tbk. diperdagangkan di Rp505 (kapitalisasi pasar 17,11 T, volume 24 jam 11,9 jt). Perbedaan utamanya: Super Bank Indonesia Tbk. jauh lebih besar — sekitar 103,1× kapitalisasi pasar Brigit Biofarmaka Teknologi Tbk., dan Super Bank Indonesia Tbk. lebih aktif diperdagangkan (11,9 jt vs 324 rb). Mana yang lebih baik tergantung tujuan investasimu.
| OBAT | SUPA | |
|---|---|---|
Kapitalisasi Pasar | 166,01 M | 17,11 T |
Volume | 324 rb | 11,9 jt |
Lot | 3,24 rb | 119,04 rb |
Perputaran | 77,68 jt | 6 M |
Harga Rata-rata | 239,75 | 504,24 |
Nilai Transaksi | 77,68 jt | 6 M |
Harga Ekuilibrium Indikatif | 240 | 505 |
Volume Ekuilibrium Indikatif | 1 | 1,29 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Selengkapnya di halaman OBAT →PT Super Bank Indonesia Tbk. (hereinafter referred to as the Bank) formerly under the name of PT Bank Fama International was established by Deed No. 36 on 5 March 1993, before Notary Herlien, S.H. The Bank has received a license as a commercial bank according to the Decree of the Minister of Finance of the Republic of Indonesia No. 834/KMK.017/1993 dated 11 October 1993.
Selengkapnya di halaman SUPA →